Open access

106 Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion
Erica Braverman, Andrea Dobbs, Darlene Monlish, Craig Byersdorfer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A66-A67; DOI: 10.1136/jitc-2020-SITC2020.0106
107 Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay
Lu Bai, Kevin Nishimoto, Mustafa Turkoz, Marissa Herrman, Jason Romero, Daulet Satpayev, Stewart Abbot, Sandra Hayes, Mary Brodey

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A67; DOI: 10.1136/jitc-2020-SITC2020.0107
108 MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro
Sashi Kasimsetty, Himavanth Gatla, Dhana Chinnasamy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A67-A68; DOI: 10.1136/jitc-2020-SITC2020.0108
109 Dominant-negative TGFβ receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma
Nina Chu, Michael Overstreet, Ryan Gilbreth, Lori Clarke, Christina Gesse, Eric Tu, Letizia Giardino, Gordon Moody

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A68; DOI: 10.1136/jitc-2020-SITC2020.0109
110 In-depth characterization of variability in apheresis collections from normal donor populations for allogeneic cell therapy
Shawn Fahl, Shawn Fahl, Shawn Fahl

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A68-A69; DOI: 10.1136/jitc-2020-SITC2020.0110
111 Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL
Jason Gehrke, Aaron Edwards, Ryan Murray, Angelica Messana, Lindsey Coholan, Henry Poulin, Melissa Le, Alden Ladd, Mark Naniong, Faith Musenge, Adam Camblin, Yeh-Chuin Poh, Sarah Smith, Giuseppe Ciaramella

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A69; DOI: 10.1136/jitc-2020-SITC2020.0111
112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy
Letizia Giardino, Ryan Gilbreth, Cui Chen, Erin Sult, Noel Monks, Ravinder Tammali, Jon Chesebrough, Kevin Schifferli, Nina Chu, Jessica Tong, Lori Clarke, Christina Gesse, Xiao-Tao Yao, Karma DaCosta, Kapil Vashisht, Gordon Moody

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A69-A70; DOI: 10.1136/jitc-2020-SITC2020.0112
12 Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice
Jun Zhou, Shuang Zhu, Hongjuan Zhang, Lei Zheng, Mingfa Zang, Annie Xiaoyu An, Shuzong Wang, Davy Xuesong Ouyang, Henry Li, Yujun Huang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A7; DOI: 10.1136/jitc-2020-SITC2020.0012
114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing
John Goulding, Mochtar Pribadi, Robert Blum, Wen-I Yeh, Yijia Pan, Svetlana Gaidarova, Chia-Wei Chang, Hui-Yi Chu, Ellen Liu, Shohreh Sikaroodi, Lucas Ferrari de Andrade, Lauren Fong, Janel Huffman, Tom Lee, Ryan Bjordahl, Kai Wucherpfennig, Bahram Valamehr

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A70-A71; DOI: 10.1136/jitc-2020-SITC2020.0114
113 Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells
Erica Goddard, Shivani Srivastava, Stanley Riddell, Cyrus Ghajar

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A70; DOI: 10.1136/jitc-2020-SITC2020.0113

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages